Lansoprazole in treatment of duodenal ulcer desease
https://doi.org/10.21518/2079-701X-2019-3-125-129
Abstract
The duodenum ulcer disease (DUD) has high specific weight among digestive tract pathologies, influencing working capacity and quality of life of patients. Now the tendency of increase in mortality and complications of DUD against the background of decrease in incidence is characteristic of Russia.
For the purpose of identification of the patients infected with H. pylori and also purposes of the most effective H. pylori therapy by him are accepted the recommendations developed by the V Maastricht consensus (Management of Helicobacter pylori infection – the Maastricht V/Florence Consensuns report).
Besides H. pylori therapy to patients the medicines promoting maintenance intragastric рН > 3 not less than 18–20 hours a day are also appointed. Such effect PPI, antacids and H2-receptor antagonists have. PPI are characterized by more expressed antisecretory action and do not cause a tachyphylaxis, than favourably differ from histamine H2-receptor antagonists.
Lancid (lansoprazole) – medicine from the PPI group. It is shown to application for treatment of DUD and for an eradication of H. pylori at the infected patients with erosive and ulcer damages of a stomach and duodenum (as a part of complex therapy). Lansoprazole as a part of Lancid promotes faster healing of ulcer defects and decrease in clinically expressed symptomatology in comparison with omeprazole and pantoprazole.
About the Authors
V. V. Skvortsov
Federal State Budgetary Educational Institution of Higher Education «Volgograd State Medical University» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Associate Professor of the Chair for Propaedeutics of Internal Diseases,
400131, Volgograd, pl. Pavshikh Bortsov, 1
O. V. Fateeva
Federal State Budgetary Educational Institution of Higher Education «Volgograd State Medical University» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
a 5th year student,
400131, Volgograd, pl. Pavshikh Bortsov, 1
E. M. Skvortsova
Medsi Clinic, Volgograd Branch
Russian Federation
Russian Federation
general practitioner,
400131, Volgograd, Lenina St., 92
References
1. Ivashkin V.T., Sheptulin A.A., Maev I.V., Baranskaya E.K., Trukhmanov A.S., Lapina T.L, et al. Clinical guidelines of the Russian Gastroenterological Association for the diagnosis and treatment of peptic ulcer. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2016;2 (6):40-54. (In Russ).
2. Shirinskaya N.V. Gastroduodenal ulcer in the Russian Federation. Morbidity and mortality. Dal’nevostochny Meditsinsky Zhurnal. 2016;3:105-109. (In Russ).
3. Kanotra R., Ahmed M., Patel N., Thakkar B., Solanki S., Tareen S. et al. Seasonal Variations and Trends in Hospitalization for Peptic Ulcer Disease in the United States: A 12-Year Analysis of the Nationwide Inpatient Sample. Cureus. 2016 Oct 30;8(10):e854.
4. Cryer B., Mahaffey K.W. Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment. J. Multidiscip. Healthc. 2014;7:137-146.
5. Nartaeva A.E., Iminjanov R.A. The morphological characteristics of gastroduodenal ulcer based on autopsy material. Vestnik KazNMU. 2013;2:259-261. (In Russ).
6. Periti P., Tonelli F., Capurso L., Nicoletti P. Managing Helicobacter pylori infection in the new millennium: a review. J. Chemotherapy. 1999;11(Suppl 4):3-55.
7. Ernst P.B., Gold B.D. The Disease Spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Ann Rev Microbiol. 2000;615-40.
8. Blaser M.J. Clinical review. Science, medicine, and the future. Helicobacter pylori and gastric diseases. BMJ. 1998;316:1507-10.
9. Shkitin V.A., Shpirna G.N., Starovoytov G.N. The role of Helicobacter pylori in human pathology. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya. 2002;4(2):128- 145. (In Russ).
10. Aruin L.I., Kapuller L.L., Isakov V.A. Morphological diagnosis of gastrointestinal diseases. M.: Triada-X, 1998. (In Russ).
11. Raiha I., Kemppainen H., Kaprio J., Koskenvuo M., Sourander L. Lifestyle, stress, and genes in peptic ulcer disease: a Nationwide Twin Cohort Study. Arch Intern Med. 1998;158:698-704.
12. Henriksson A.E., Edman A.C., Nillson I., Bergquist D., Wadstrom T. Helicobacter pylori and the relation to other risk factors in patients with acute bleeding peptic ulcer. Scand J Gastroenterol. 1998;33:1030-3.
13. Levenstein S. Stress and peptic ulcer: life beyond helicobacter. BMJ. 1998;316:538-41.
14. Brzozowska I., Ptak-Belowska A., Pawlik M., Pajdo R., Drozdowicz D., Konturek S.J. et al. Mucosal strengthening activity of central and peripheral melatonin in the mechanism of gastric defense. J Physiol Pharmacol. 2009 Dec;60(Suppl 7):47-56.
15. Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T. et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30.
16. Ivashkin V.T., et al. Prevention and treatment of chronic diseases of the upper gastrointestinal tract. M.: MEDpress-inform, 2014:9-59. (In Russ).
17. Katashima M., Yamamoto K., Tokuma Y., Hata T., Sawada Y., Iga T. Comparative pharmacokinetic/ pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans. Eur. J. Drug. Metab. Pharmacokinet. 1998;23:19-26
18. Lapina T.L. Proton pump inhibitors: from pharmacological properties to clinical practice. Pharmateca. 2002;9:11–16. (In Russ).
19. Vasilyev Yu.V. Proton pump inhibitors. Lechaschy Vrach. 2007;1:16. (In Russ).
20. Farber A.V., Nikonov E.L. Proton pump inhibitors: off label situations. Remedium. 2010;2:26-31. (In Russ).
21. Isakov V.A. Therapy of acid-related diseases with proton pump inhibitors in questions and answers. Consilium Medicum. 2006;7:3-7. (In Russ).
22. Florent С., Forestier S. Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30 mg and pantoprazole 40 mg. European Journal of Gastrooenterology & Нepatology. 1997 Feb 01;9(2):195-200.
23. Olmos J., Rios H. et al. Lansoprazole is faster then omeprazole in duodenal ulcer healing. Ibid. 1997;41(suppl.3):A98.
Review
For citations:
Skvortsov VV, Fateeva OV, Skvortsova EM. Lansoprazole in treatment of duodenal ulcer desease. Meditsinskiy sovet = Medical Council. 2019;(3):125-129. (In Russ.) https://doi.org/10.21518/2079-701X-2019-3-125-129
Views:
712
Email this article 